Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

431 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Löwenberg B. Döhner H, et al. Among authors: dinardo cd. Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867. Blood. 2022. PMID: 35797463 Free article.
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.
DiNardo CD, Propert KJ, Loren AW, Paietta E, Sun Z, Levine RL, Straley KS, Yen K, Patel JP, Agresta S, Abdel-Wahab O, Perl AE, Litzow MR, Rowe JM, Lazarus HM, Fernandez HF, Margolis DJ, Tallman MS, Luger SM, Carroll M. DiNardo CD, et al. Blood. 2013 Jun 13;121(24):4917-24. doi: 10.1182/blood-2013-03-493197. Epub 2013 May 2. Blood. 2013. PMID: 23641016 Free PMC article. Clinical Trial.
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, Dinardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R, Orazi A. Wang SA, et al. Among authors: dinardo cd. Blood. 2014 Apr 24;123(17):2645-51. doi: 10.1182/blood-2014-02-553800. Epub 2014 Mar 13. Blood. 2014. PMID: 24627528 Free PMC article.
Getting a handle on hereditary CEBPA mutations.
DiNardo CD. DiNardo CD. Blood. 2015 Sep 3;126(10):1156-8. doi: 10.1182/blood-2015-07-657908. Blood. 2015. PMID: 26337351 Free article. No abstract available.
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannan Z, Pierce S, Jabbour EJ, Ravandi F, Daver N, Luthra R, Kantarjian H, Garcia-Manero G. Badar T, et al. Leuk Res. 2015 Dec;39(12):1367-74. doi: 10.1016/j.leukres.2015.10.005. Epub 2015 Oct 19. Leuk Res. 2015. PMID: 26547258 Free PMC article.
Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC).
DiNardo CD, Bannon SA, Routbort M, Franklin A, Mork M, Armanios M, Mace EM, Orange JS, Jeff-Eke M, Churpek JE, Takahashi K, Jorgensen JL, Garcia-Manero G, Kornblau S, Bertuch A, Cheung H, Bhalla K, Futreal A, Godley LA, Patel KP. DiNardo CD, et al. Clin Lymphoma Myeloma Leuk. 2016 Jul;16(7):417-428.e2. doi: 10.1016/j.clml.2016.04.001. Epub 2016 Apr 27. Clin Lymphoma Myeloma Leuk. 2016. PMID: 27210295 Free PMC article.
Mutations in AML: prognostic and therapeutic implications.
DiNardo CD, Cortes JE. DiNardo CD, et al. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):348-355. doi: 10.1182/asheducation-2016.1.348. Hematology Am Soc Hematol Educ Program. 2016. PMID: 27913501 Free PMC article. Review.
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.
Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Abaza Y, et al. Blood. 2017 Mar 9;129(10):1275-1283. doi: 10.1182/blood-2016-09-736686. Epub 2016 Dec 21. Blood. 2017. PMID: 28003274 Free PMC article. Clinical Trial.
More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.
Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. Montalban-Bravo G, et al. Blood. 2017 May 4;129(18):2584-2587. doi: 10.1182/blood-2016-11-749903. Epub 2017 Feb 28. Blood. 2017. PMID: 28246192 Free PMC article. Clinical Trial. No abstract available.
431 results